GRF:BME
Grifols SA Class A
€10.17
arrow_upward
+0.89%(+0.090) 1D
Oct 23, 4:36:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€10.06
High
€10.17
Low
€10.03
Mkt. cap
6.11B
Avg. vol.
1.32M
Volume
1.42M
Dividend
2.28%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.29
52-wk high
€11.70
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€10.06
High
€10.17
Low
€10.03
Mkt. cap
6.11B
Avg. vol.
1.32M
Volume
1.42M
Dividend
2.28%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.29
52-wk high
€11.70
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
Cassandra Unchained | Michael Burry
·
15 hours ago
Foundations: The Fate of the S&P 500’s Worst Stocks, the Y2K Analogue, and Time for Small Caps?
Yardeni QuickTakes
·
8 hours ago
US MARKETS CALL: Still Proceeding Cautiously
Investor's Business Daily
·
7 hours ago
What To Do In A Doom-And-Bloom Market; 3 Titans Loom
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A